In recent months, the US Food and Drug Administration (FDA) has issued two warnings about potential Multaq side effects. Those side effects reportedly include an increased risk of Multaq liver failure and Multaq heart failure. Multaq is known generically as dronedarone and is made by Sanofi Aventis.
FREE CASE EVALUATION
Send your Multaq claim to a Lawyer who will review your case at NO COST or obligation. 
Sanofi Aventis Multaq FDA Approval for AFib
Multaq was approved in the US in July 2009 for the treatment of atrial flutter and paroxysmal or persistent atrial fibrillation, both of which can result in stroke. It was not approved for permanent atrial fibrillation, which was the focus of the PALLAS study (below). Multaq is made by Sanofi Aventis. According to the FDA, between July 2009 and October 2010, more than 600,000 dronedarone prescriptions were filled.
Multaq Liver Damage
In July, 2011, the FDA issued a warning to doctors and patients regarding the potential risk of liver damage associated with Multaq. According to the FDA news release (07/21/11), the agency received reports of liver damage in patients who took Multaq pills, including two reports of patients undergoing liver transplant. Both patients who required liver transplantation were over 70 years old, had no preexisting liver problems and had taken Multaq for between four and six months.
Symptoms of severe liver injury include weakness, shortness of breath, stomach pain, difficulty breathing, rapid weight gain and diarrhea.
Multaq Heart Problems
In December 2011, the FDA announced that trials on Multaq linked the medication to a serious risk of cardiovascular problems, which included an increased risk of death. As a result, the FDA has altered the warning label to include information about those risks. Specifically, the label will now carry the warning:
"Healthcare professionals should not prescribe Multaq to patients with Permanent Atrial Fibrillation who cannot or will not be converted into normal sinus rhythm (permanent AF), because Multaq doubles the rate of cardiovascular death, stroke and heart failure in such patients."
Furthermore, FDA warned that patients should have their heart rhythm monitored every three months and treatment with Multaq should stop if the patient is in AF.
FDA Review of Multaq AFib Study (PALLAS)
In 2011, the FDA announced that it was reviewing data from a clinical trial that studied the effects of Multaq in patients with permanent atrial fibrillation (AFib). The Permanent Atrial fibriLLAtion Outcome Study Using Dronedarone on Top of Standard Therapy (PALLAS) study, undertaken by Sanofi Aventis, was halted early after an analysis of data found a two-fold increase in death, stroke and hospitalization in patients who took Multaq when compared with patients who took a placebo.
The FDA is now evaluating whether the preliminary results of the PALLAS study apply to patients who take Multaq for paroxysmal or persistent atrial fibrillation or atrial flutter.
Multaq Heart Risk for AFib Patients (Health Canada)
In July 2011, Health Canada announced it was also reviewing information regarding the risk of Multaq side effects. In making its announcement, Health Canada noted that in Canada, "Multaq is authorized only for the treatment of patients with a history of, or who currently have various forms of intermittent atrial fibrillation ('non-permanent atrial fibrillation')."
Symptoms of worsening heart failure include shortness of breath at rest, wheezing at rest, chest tightness, trouble sleeping, weight gain, foot or leg swelling and trouble breathing while asleep.
Multaq Interactions and Side Effects
According to the Multaq website (www.multaq.com), common Multaq side effects include stomach problems, nausea, diarrhea, vomiting, indigestion, tiredness, weakness, rash and itching.
Multaq can interact with:
- Nefazodone
- Voriconazole
- Ritonavir
- Telithromycin
- Ketoconazole
- Clarithromycin
- Itraconazole
- Cyclosporine
Furthermore, when the following medications are taken with Multaq, patients can experience a dangerous abnormal heart rhythm:
- Phenothiazines
- Tricyclic antidepressants
- Certain medicines used to treat abnormal heart rhythm or fast heartbeat
- Certain antibiotics
Multaq Side Effects Legal Help
If you or a loved one has suffered damages in this case, please click the link below and your complaint will be sent to a lawyer who may evaluate your claim at no cost or obligation.
Last updated on May-22-12 |
MULTAQ ARTICLES AND INTERVIEWS
"Multaq Not a Very Safe Drug"
 Louisville, KY: Any doctor will tell you that every drug has side effects—including heart drug Multaq. In fact, Multaq side effects are compelling. But even though the US Food and Drug Administration (FDA) has Multaq under a microscope and issued a cautionary statement about dronedarone (Multaq) as recently as February, the agency is resisting any effort to request a Multaq recall.
[READ MORE]
Is Multaq Worth the Risks?
 Boston, MA: When patients deal with serious drug side effects, such as Multaq side effects, they often assume that, despite the side effects, they are taking the best medication available, making the side effects a necessary evil. But for people suffering from Multaq problems, especially in the face of recent Multaq warnings, news that Multaq may not have been the best drug is probably surprising [READ MORE]
Multaq Concerns Reverberate through the Cardiology Community
 Washington, DC: The concern over Multaq side effects has, not surprisingly, made it to the pages of Cardiology News (2/12). Ever since the US Food and Drug Administration (FDA) issued a health alert last December with regard to dronedarone (Multaq) and the risk to patients with permanent atrial fibrillation (AF), the cardiology world is proceeding with renewed caution over the Multaq portfolio [READ MORE]
YOUR MULTAQ STORIES
Publish your Multaq experience here for our readers to learn from.
|
